Keith A. A. Fox

Keith A. A. Fox

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Keith A. A. Fox

Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MPManesh R. Patel
Manesh R. Patel
KMKenneth W. Mahaffey
Kenneth W. Mahaffey
JGJyotsna Garg
Jyotsna Garg
GPGuohua Pan
Guohua Pan
DSDaniel E. Singer
Daniel E. Singer
TCthe ROCKET AF Steering Committee
the ROCKET AF Steering Committee
The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin. In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism. In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 for noninferiority). In the intention-to-treat analysis, the primary end point occurred in 269 patients in the rivaroxaban group (2.1% per year) and in 306 patients in the warfarin group (2.4% per year) (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P<0.001 for noninferiority; P=0.12 for superiority). Major and nonmajor clinically relevant bleeding occurred in 1475 patients in the rivaroxaban group (14.9% per year) and in 1449 in the warfarin group (14.5% per year) (hazard ratio, 1.03; 95% CI, 0.96 to 1.11; P=0.44), with significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, P=0.02) and fatal bleeding (0.2% vs. 0.5%, P=0.003) in the rivaroxaban group. In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.)

1 August 2001 in The Lancet
Verified
Journal Article
Closed access
SMShamir R Mehta
Shamir R Mehta
SYSalim Yusuf
Salim Yusuf
RPRon Jg Peters
Ron Jg Peters
MBMichel E Bertrand
Michel E Bertrand
BLBasil S Lewis
Basil S Lewis
KFKeith Aa Fox
Keith Aa Fox

20 April 2006 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
DBDeepak L Bhatt
Deepak L Bhatt
KFKeith A A Fox
Keith A A Fox
WHWerner Hacke
Werner Hacke
PBPeter B Berger
Peter B Berger
HBHenry R Black
Henry R Black
CICHARISMA Investigators
CHARISMA Investigators
Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes. The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent and 17.9 percent (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.995; P=0.04), and the rate of severe bleeding was 1.7 percent and 1.3 percent (relative risk, 1.25; 95 percent confidence interval, 0.97 to 1.61 percent; P=0.09). The rate of the primary end point among patients with multiple risk factors was 6.6 percent with clopidogrel and 5.5 percent with placebo (relative risk, 1.2; 95 percent confidence interval, 0.91 to 1.59; P=0.20) and the rate of death from cardiovascular causes also was higher with clopidogrel (3.9 percent vs. 2.2 percent, P=0.01). In the subgroup with clinically evident atherothrombosis, the rate was 6.9 percent with clopidogrel and 7.9 percent with placebo (relative risk, 0.88; 95 percent confidence interval, 0.77 to 0.998; P=0.046). In this trial, there was a suggestion of benefit with clopidogrel treatment in patients with symptomatic atherothrombosis and a suggestion of harm in patients with multiple risk factors. Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)

5 October 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JEJohn W. Eikelboom
John W. Eikelboom
SCStuart J. Connolly
Stuart J. Connolly
JBJackie Bosch
Jackie Bosch
GDGilles R. Dagenais
Gilles R. Dagenais
RHRobert G. Hart
Robert G. Hart
SYSalim Yusuf
Salim Yusuf
We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424.)

27 November 2007 in Circulation
Verified
Journal Article
Closed access
KTKristian Thygesen
Kristian Thygesen
JAJoseph S Alpert
Joseph S Alpert
HWHarvey D White
Harvey D White
JIJoint Esc/accf/aha/whf Task Force For The Redefinition Of Myocardial Infarction
Joint Esc/accf/aha/whf Task Force For The Redefinition Of Myocardial Infarction
AJAllan S Jaffe
Allan S Jaffe
NANawwar Al-Attar
Nawwar Al-Attar

27 October 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
CGChristopher B Granger
Christopher B Granger
RGRobert J Goldberg
Robert J Goldberg
ODOmar Dabbous
Omar Dabbous
KPKaren S Pieper
Karen S Pieper
KEKim A Eagle
Kim A Eagle
GIGlobal Registry of Acute Coronary Events Investigators
Global Registry of Acute Coronary Events Investigators
ACUTE CORONARY syndromes (ACS) represent the most common cause of death in the western world.1,2 Considerable variability exists in the risk for adverse events across the spectrum of ACS. Different presenting characteristics, in large part related to identification of varying levels of risk, have become important factors in deciding on the level of care and choice of interventional and medical therapies.3-5 Current guidelines from the American College of Cardiology/American Heart Association3,4 and the European Society of Cardiology6 recommend that certain pharmacological and interventional strategies are most appropriate for higher-risk groups. Despite these recommendations, some contemporary registry data suggest that more aggressive therapy is not necessarily targeted at higher-risk patients, even in more cost-constrained health care systems.7 Although individual demographic and clinical characteristics may be associated with an increased risk for adverse outcomes, one must take multiple factors into account simultaneously to optimize the ability to assess risk accurately.